PCLAF抗体;PCLAF Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P13704(PCLAF Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

The PCLAF (PCNA-associated Longevity Assurance Factor) antibody targets a protein also known as KIAA0101 or p15PAF, which plays a critical role in cell cycle regulation and DNA replication. PCLAF interacts with proliferating cell nuclear antigen (PCNA), a key protein involved in DNA synthesis and repair. This interaction enables PCLAF to regulate the stability and function of PCNA during DNA replication, particularly in rapidly dividing cells. Structurally, PCLAF contains a conserved PCNA-binding motif, facilitating its role in DNA damage response and cell proliferation.

Overexpression of PCLAF is strongly associated with various cancers, including hepatocellular carcinoma, lung cancer, and colorectal cancer. It promotes tumorigenesis by enhancing cell proliferation, inhibiting apoptosis, and supporting genomic instability. Studies suggest that PCLAF upregulation correlates with poor prognosis, making it a potential biomarker for cancer diagnosis and therapeutic targeting. Conversely, its expression in normal tissues is typically low or undetectable, underscoring its cancer-specific relevance.

PCLAF antibodies are widely used in research to investigate its biological functions and mechanisms in cancer progression. They enable detection of PCLAF expression via techniques like Western blotting, immunohistochemistry, and flow cytometry. Additionally, these antibodies aid in exploring PCLAF's interaction networks and evaluating its role as a candidate for small-molecule inhibitors or gene therapy in oncology. Ongoing studies continue to clarify its regulatory pathways and clinical applications.